BC
LJPC

Broadfin Capital’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Broadfin Capital’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100,000
Closed -$2.01M – 62
2018
Q3 		$2.01M Buy
+100,000
New +$2.61M 0.3% 48
2017
Q3 		– Sell
-150,000
Closed -$4.47M – 63
2017
Q2 		$4.47M Buy
+150,000
New +$4.3M 0.54% 36

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Broadfin Capital's LJPC Position: Q4 2019 in Review

Broadfin Capital increased its La Jolla Pharmaceutical Company (LJPC) stake by 1,378% in Q4 2019, buying an estimated $14.8M and bringing the position to 2,688,068 shares worth $10.6M. The position accounts for 1.41% of the portfolio, ranked #23.

Broadfin Capital first reported a position in LJPC in Q1 2014 and has held it in 24 quarters since. The position peaked at $49.3M in Q1 2018. 77 funds tracked by Wall St. Rank hold LJPC as of Q4 2019.

  • Broadfin Capital held 2,688,068 shares of La Jolla Pharmaceutical Company worth $10.6M as of Q4 2019.
  • Broadfin Capital bought 2,506,224 La Jolla Pharmaceutical Company shares in Q4 2019, an estimated $14.8M.
  • La Jolla Pharmaceutical Company made up 1.41% of Broadfin Capital's portfolio in Q4 2019, its #23 holding.
  • Broadfin Capital first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and has held it in 24 quarters since.
  • Broadfin Capital's La Jolla Pharmaceutical Company position peaked at $49.3M in Q1 2018.
  • 77 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.